I am purposely creating a new post so as not to give the
I am purposely creating a new post so as not to give the impression that I am replying to anyone in particular.
Nano one time took the position to notify share holders of much of what they were doing and this back-fired in their face. Battelle was harrased with phone calls fishing for more information, whether this an attempt to sabotage the relationship, I can't say but suspect it may have been. Constant bashes about wording and meaningless items and even calling the company and berating the secretary to the point of tears. How does a piss ant, pink sheet stock deserve this attention? These appear to be tactics to me, but then what do I know, I am not an expert in stock market and business tactics and still am gullible enough to believe that most people are honest and not calculating, I am learning different and nothing surprises me anymore.
How can anyone blame them from a human standpoint for clamming up and only releasing sure things. Hear that again, sure things.
From a technology and business standpoint, what honest investor, say again, honest investor can blame Nanologix for holding their cards close to their chest and only releasing information about protected technologies and past sales history and not showing their cards or strategies for the future?
Smart, intelligent and protected.
Hopefully we are seeing some new investors, I have continued to add shares as I could throughout my 8 years and what I have spent is already absorbed financially so I will sit on what I have or buy more when I can.
Good luck to all, thank you Bret for working your 10-12 hour days, hopefully we can both retire at some not to distant future point.
George
Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Akero Therapeutics Highlights Efruxifermin's Impact on Fibrosis In an exciting development for patients battling serious metabolic diseases, Akero Therapeutics, Inc. (NASDAQ: AKRO) has shared promising results from the Phase 2b SYMMETRY trial, which investigates the effectiveness of efruxifermin (EFX) for treating compensated cirrhosis caused by metabolic...
Continue Reading
Market Reactions to Trade Tariffs The global markets are increasingly reacting to the surge in trade tensions, particularly between large economies. The introduction of tariffs on US soybeans and other agricultural products by a major global player has raised concerns for investors and businesses alike. The latest developments on the trade front could have long-lasting...
Continue Reading
ADAR1 Capital Management Issues Open Letter to Keros Board In an important communication, ADAR1 Capital Management, the largest stockholder of Keros Therapeutics (NASDAQ: KROS), has expressed its concerns regarding the Board's handling of critical company matters. Holding approximately 13.3% of the outstanding shares, ADAR1 is advocating for a more constructive dialogue...
Continue Reading
Significant Growth in Pre-Seed Bitcoin Startup Investments Recent research conducted by Trammell Venture Partners (TVP), a prominent venture capital firm based in Austin, unveils a remarkable 767% increase in pre-seed Bitcoin startup investments since 2021. This phenomenal growth indicates a rising trend of enthusiasm surrounding Bitcoin-native ventures. Although the...
Continue Reading
Bitcoin's Recent Price Movements Recently, crypto analyst Benjamin Cowen has been closely monitoring Bitcoin's performance, particularly its movements around the key support level of $79,000. He alerts investors as Bitcoin slips below this crucial threshold, indicating potential shifts in its pricing dynamics. Cowen stresses the importance of the weekly closing price in...
Continue Reading